325 related articles for article (PubMed ID: 11398905)
1. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
Cox AD
Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Sebti SM; Hamilton AD
Expert Opin Investig Drugs; 2000 Dec; 9(12):2767-82. PubMed ID: 11093352
[TBL] [Abstract][Full Text] [Related]
5. Farnesylated proteins as anticancer drug targets: from laboratory to the clinic.
Russo P; Loprevite M; Cesario A; Ardizzoni A
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):123-38. PubMed ID: 15032718
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitors: mechanism and applications.
Prendergast GC; Rane N
Expert Opin Investig Drugs; 2001 Dec; 10(12):2105-16. PubMed ID: 11772308
[TBL] [Abstract][Full Text] [Related]
7. Evolving therapies: farnesyltransferase inhibitors.
Purcell WT; Donehower RC
Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
[TBL] [Abstract][Full Text] [Related]
8. New targets for therapy in breast cancer: farnesyltransferase inhibitors.
Head J; Johnston SR
Breast Cancer Res; 2004; 6(6):262-8. PubMed ID: 15535857
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
10. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma.
Santucci R; Mackley PA; Sebti S; Alsina M
Cancer Control; 2003; 10(5):384-7. PubMed ID: 14581893
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
Baum C; Kirschmeier P
Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
[TBL] [Abstract][Full Text] [Related]
13. [Development of farsenyl transferase inhibitors as anticancer agents].
Cestac P; Doisneau-Sixou S; Favre G
Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
[TBL] [Abstract][Full Text] [Related]
14. Protein farnesyltransferase inhibitors.
Head JE; Johnston SR
Expert Opin Emerg Drugs; 2003 May; 8(1):163-78. PubMed ID: 14610919
[TBL] [Abstract][Full Text] [Related]
15. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
[TBL] [Abstract][Full Text] [Related]
16. Increasing complexity of farnesyltransferase inhibitors activity: role in chromosome instability.
Falugi C; Trombino S; Granone P; Margaritora S; Russo P
Curr Cancer Drug Targets; 2003 Apr; 3(2):109-18. PubMed ID: 12678714
[TBL] [Abstract][Full Text] [Related]
17. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive effects of farnesyl transferase inhibitors on multiple myeloma tumor cells.
Shi Y; Gera J; Hsu JH; Van Ness B; Lichtenstein A
Mol Cancer Ther; 2003 Jun; 2(6):563-72. PubMed ID: 12813136
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on farnesyl transferase inhibitors in cancer therapy.
Mazieres J; Pradines A; Favre G
Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
[TBL] [Abstract][Full Text] [Related]
20. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]